Akorn’s $4.3 Billion Acquisition by Fresenius Kabi

Cravath is representing Akorn in connection with the transaction.

On April 24, 2017, Akorn and Fresenius Kabi announced that Fresenius Kabi has agreed to acquire Akorn, a U.S.-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for approximately $4.3 billion, or $34.00 a share.

The Cravath team is led by partners Keith Hallam (Picture) and Robert I. Townsend III and includes associates G.J. Ligelis Jr. and C. Daniel Haaren on M&A matters; partner Eric W. Hilfers and associates Matthew Cantor and Aaron J. Feuer on executive compensation and benefits matters; partner Christopher K. Fargo and associate Kiran Sheffrin on tax matters; partner Matthew Morreale on environmental matters; and partners Christine A. Varney and Julie A. North and senior attorney Jesse M. Weiss on antitrust matters. Nicolas R. Yamagata also worked on M&A matters.

 

Involved fees earner: Keith Hallam – Cravath Swaine & Moore; Robert Townsend – Cravath Swaine & Moore; G.J. Ligelis Jr. – Cravath Swaine & Moore; Daniel Haaren – Cravath Swaine & Moore; Eric Hilfers – Cravath Swaine & Moore; Matthew Cantor – Cravath Swaine & Moore; Aaron Feuer – Cravath Swaine & Moore; Christopher K. Fargo – Cravath Swaine & Moore; Kiran Sheffrin – Cravath Swaine & Moore; Matthew Morreale – Cravath Swaine & Moore; Christine Varney – Cravath Swaine & Moore; Julie North – Cravath Swaine & Moore; Jesse Weiss – Cravath Swaine & Moore;

Law Firms: Cravath Swaine & Moore;

Clients: Akorn Inc.;

 

Print Friendly, PDF & Email
Avatar

Author: Ambrogio Visconti